Quantitative Computed Tomography to Assess Ventilatory and Perfusion Abnormalities in Individuals With Post-Acute Sequelae of SARS-CoV-2 Infection
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Post-Acute COVID-19
- Sponsor
- Tufts Medical Center
- Enrollment
- 40
- Locations
- 1
- Primary Endpoint
- Measures of blood volume distribution
- Status
- Recruiting
- Last Updated
- 9 months ago
Overview
Brief Summary
Prospective cohort study to evaluate the utility of quantitative CT analysis to assess ventilation and perfusion defects in patients with Post-acute Sequelae of SARS-CoV-2 (PASC) and functional limitations
Detailed Description
This is a study to describe the overall pattern of lung ventilation and perfusion defects in individuals with PASC. Subjects with PASC with a documented history of COVID-19 and persistent symptoms of fatigue, dyspnea, and/or exercise intolerance will complete questionnaires, and undergo pulmonary function tests, 6-minute walk tests, and a low dose CT chest to describe the overall pattern of lung regional ventilation and blood distribution and to compare this pattern to asymptomatic controls with and without prior COVID-19.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Self-reported or documented SARS-CoV-2 infection by RT-PCR or Antigen testing \> 3 months ago or no previous history of SARS-CoV-2 infection (control group only)
- •Normal or mild abnormalities on baseline Pulmonary Function Tests (PFTs)
- •New or worsening symptoms of chronic fatigue, dyspnea or exercise intolerance after COVID-19 with otherwise unclear etiology (PASC group only)
Exclusion Criteria
- •SARS-CoV-2 infection by RT-PCR or Antigen testing within the last 3 months
- •Inability to provide consent or non-English speaking
- •Pregnancy
- •Any respiratory infection in last 4 weeks
- •PFT relative contraindications
- •History of major cardiovascular, pulmonary, renal, hepatic, autoimmune or neuromuscular disease including asthma, COPD, interstitial lung disease, heart failure, pulmonary arterial hypertension, or prior pulmonary embolism
- •Active malignancy undergoing treatment or history of malignancy involving the lung
Outcomes
Primary Outcomes
Measures of blood volume distribution
Time Frame: 1 day
Measures of regional lung ventilation
Time Frame: 1 day
Secondary Outcomes
- Fatigue severity scores(1 day)
- Quality of life scores(1 day)
- Six-minute walk distance(1 day)
- Dyspnea severity scores(1 day)